Insights
The latest research insights, model validations, and scientific updates from Jitian Bio.
Tumor immunology
Tumor-immunology domain studying how host genetic background shapes response to cancer immunotherapy in diverse mouse F1 panels; published work used DO×B6 F1 for the main screen and CC×B6 F1 for validation of genetically controlled checkpoint-inhibitor responses in syngeneic tumor models.
Read moreInfection immunology and inflammatory responses
Basic research on immune responses and inflammatory regulation, featuring a non-live-pathogen inflammatory reference model.
Read moreAutoimmunity, inflammation and idiosyncratic drug toxicity
Domain entry for immune-mediated inflammation and idiosyncratic drug toxicity, covering two literature directions: CC spontaneous-colitis line CC011/Unc as an intestinal inflammation reference, and the CC multi-strain panel for tolvaptan idiosyncratic liver-injury susceptibility.
Read moreCNS injury and axon regeneration
Research on axon growth and repair after central nervous system injury. Published comparisons of the CAST/Ei and C57BL/6 inbred strains provide a reference for genetic-background effects on CNS regeneration.
Read moreImmune checkpoint inhibitor response and resistance
Variability of response and primary resistance to cancer immune checkpoint inhibition, studied in genetically diverse mouse F1 populations.
Read moreSpontaneous solid tumors
Spontaneous solid-tumor susceptibility in a genetically diverse mouse population: published surveillance across multiple Collaborative Cross (CC) strains showed broad variation in spontaneous tumor incidence and spectrum, and identified CC036 as a spontaneous gastric-tumour model.
Read moreIdiosyncratic drug-induced liver and kidney injury
Domain entry for idiosyncratic drug-induced liver injury (DILI): published work used the CC multi-strain panel (45 strains) to study tolvaptan-induced liver injury susceptibility and biomarkers; ADPKD is only the clinical context of the drug, and no kidney-injury model evidence is cited for this entry.
Read moreARRIVE 2.0 animal research reporting: a guide to the official guidelines
Core reporting items, planned versus performed research, and official sources.
Read more